Enable Accessibility Enable Accessibility

Quarterly Results FY2021 (April 2021-March 2022)

Earnings Results for FY2021 (May 11, 2022)

Document Q1 Q2 Q3
Q4
Press Release

PDF.png**

PDF.png

PDF.png

PDF.png

Presentation

PDF.png***

PDF.png

PDF.png

PDF.png

Quarterly Financial Report PDF.png*** PDF.png PDF.png PDF.png
  (Supplementary Information) Reconciliation from Reported to Core/Underlying Core microphone.png*** microphone.png microphone.png microphone.png

(Supplementary Information) Supplementary Financial Information

microphone.png microphone.png microphone.png microphone.png

Webcast

microphone.png** microphone.png microphone.png microphone.png
Financial Statements (Tokyo Stock Exchange filing) PDF.png**** PDF.png PDF.png PDF.png
Annual Securities Report / Quarterly Securities Report * PDF.png PDF.png PDF PDF
Form 20-F (SEC filing) - - - PDF


Clinical trial summary (updated May 11, 2022) PDF

Epidemiology data (updated May 11, 2022) PDF

* The English version of the Annual Securities Report/Quarterly Securities Report is provided as a reference material to assist foreign investors in understanding the Securities Report, which was filed with Japanese FSA (Financial Services Agency). We do not provide assurance about the accuracy, validity, or coverage of the English translation of this document, and if the description and explanation of this document differs from those of the Japanese Annual Securities Report/Quarterly Securities Report which was filed, the Securities Report in Japanese shall prevail.

 

** Certain financial information in this press release and webcast, as applicable, is out-of-date as a result of a decision that Takeda received from the Irish Tax Appeals Commission related to the treatment of a break fee received by Shire plc in October 2014 from AbbVie Inc.  Please see Takeda’s August 2, 2021 press release for information related to the Irish Tax Appeals Commission’s decision and Takeda’s August 6, 2021 press release for details of the revisions to its previously disclosed financial information.

 

*** This document, which was originally published on July 30, 2021, was revised on August 6, 2021 as a result of a decision that Takeda received from the Irish Tax Appeals Commission.  Please see Takeda’s August 2, 2021 press release for information related to the Irish Tax Appeals Commission’s decision and Takeda’s August 6, 2021 press release for details of the revision.

 

**** This document, which was originally filed with the Tokyo Stock Exchange on July 30, 2021, has been updated as a result of a decision that Takeda received from the Irish Tax Appeals Commission and re-filed with Tokyo Stock Exchange on August 6, 2021.  Please see Takeda’s August 2, 2021 press release for information related to the Irish Tax Appeals Commission’s decision and Takeda’s August 6, 2021 press release for details of the revision.

 

Financial Results Archive